RegenExtracell (Extracell BMC) — autologous bone marrow concentrate, processed intraoperatively in one step to retain the marrow’s mesenchymal stromal cells. For reconstructive and orthop
Request clinical documentation or distributor information for your region.
RegenExtracell is RegenLab’s technology for concentrating bone marrow. Prepared intraoperatively as an autologous bone marrow concentrate (BMC), it isolates the marrow’s own repair cells for use in reconstructive and orthopedic surgery — the one product in the range made from marrow rather than blood.
RegenExtracell departs from the rest of the range in its starting material. Where the PRP products are made from a blood draw, the Extracell BMC kit processes bone marrow aspirate — the fluid tissue drawn, typically from the iliac crest, during surgery. That aspirate is rich not only in mature blood cells but in a heterogeneous population of multipotent cells, including the mesenchymal stromal cells (MSCs) that are precursors of musculoskeletal tissue. The kit uses RegenTHT tubes, built on the same principle as the rest of the platform: a biologically inert separating gel of a specific density that isolates the plasma and the mononuclear-cell fraction — where the MSCs sit — from the other marrow elements. The output is an autologous bone marrow concentrate. No reagent beyond the anticoagulant is added, and nothing leaves the closed system.
The defining feature is that the whole thing happens in the operating room, during the same procedure. Bone marrow is aspirated under strict aseptic technique, processed by a single short centrifugation in the RegenTHT tubes, and the resulting concentrate is reimplanted at the lesion site before the surgery is closed — a “one-step therapy”. Crucially, this avoids the alternative pathway of sending cells to a laboratory for selection and culture expansion, with its cost, delay and regulatory weight; the patient’s own regenerative cells are concentrated and returned in a single sitting. Because the separation is mechanical and standardised by the gel, the large majority of the mesenchymal stromal cells are recovered in a reproducible way. It is a surgical, specialist workflow — not a chairside injection like the other products in the range.
What sets RegenExtracell apart is the cell population it delivers. Isolated in the concentrate, the mesenchymal stromal cells form fibroblast colony-forming units in vitro and can differentiate along osteogenic, chondrogenic and adipogenic lines — that is, toward bone, cartilage and related tissue. Transferring that regenerative potential directly to the site of a lesion is the therapeutic rationale, which is why the product sits in reconstructive and orthopedic-surgical use rather than in the office-based indications. It is also a different regulatory object: where Cellular Matrix is a Class III device, the Extracell BMC kit is CE-marked in a different class, reflecting its surgical, autologous, minimally-manipulated nature. Underlying it is the same RegenLab separating-gel principle that standardises every product in the range — here applied to marrow rather than blood.
RegenExtracell is the technology behind RegenLab’s surgical indication, Surgical Bone Reconstruction. Its use is operative: bone reconstruction and orthopedic or traumatological procedures — non-union and delayed-union fractures, bone defects, osteonecrosis, osteochondral lesions and fusion augmentation — where the marrow concentrate is delivered intraoperatively, usually alongside a graft or scaffold, to add living regenerative cells to the repair. This is a distinct clinical territory from the chairside, injection- and gel-based indications, which is why it has its own surgical hub rather than sharing one with the office-based orthopedics page. That hub carries the clinical rationale, the operative workflow and the evidence; this page stays focused on the device and how the concentrate is produced. For the indication-level detail, see the Surgical Bone Reconstruction section.
It starts from bone marrow aspirate rather than a blood draw, and yields a bone marrow concentrate rich in mesenchymal stromal cells — used surgically, not injected chairside.
In the operating room, in one step during the same procedure — with no laboratory cell selection or culture expansion.
The mononuclear-cell fraction, including the mesenchymal stromal cells (MSCs) with osteogenic, chondrogenic and adipogenic potential.
Reconstructive, orthopedic and traumatological surgery — supporting bone and cartilage repair. It is not one of the chairside injection or gel indications.
Yes — CE-marked as an autologous bone marrow processing kit; its device class differs from Cellular Matrix.